Frontiers Case report: Short-term eculizumab use in atypical HUS

atypical hemolytic uremic syndrome - List of Frontiers' open access articles

PDF] Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Eculizumab Use for Kidney Transplantation in Patients With a Diagnosis of Atypical Hemolytic Uremic Syndrome - ScienceDirect

Short-term use of Soliris treats two cases of aHUS not tied to mutations

Diagnostic and Risk Factors for Complement Defects in Hypertensive Emergency and Thrombotic Microangiopathy

Defining treatment duration in atypical hemolytic uremic syndrome in adults: a clinical and pathological approach.

Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era

The treatment of atypical hemolytic uremic syndrome with eculizumab in pediatric patients: a systematic review

Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic Syndrome

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use

PDF) Eculizumab in Typical Hemolytic Uremic Syndrome (HUS) With Neurological Involvement

Frontiers Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults